Haematological Malignancies, Multiple Myeloma
Shaji Kumar, ASH 2022: Highlights in high-risk newly-diagnosed multiple myeloma
Watch Time: 3 mins
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of high-risk newly-diagnosed multiple myeloma, where it is fundamental to risk stratify patients and develop different treatment strategies. Abstract 752: Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction […]